---
title: "GEMPHARMATECH released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, a year-on-year increase of 11.9%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262206753.md"
description: "According to the Zhitong Finance APP, GEMPHARMATECH disclosed its third-quarter report for 2025. The company achieved revenue of 576 million yuan in the first three quarters, a year-on-year increase of 12.92%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 11.9%; the net profit excluding non-recurring gains and losses was 92.79 million yuan, a year-on-year increase of 29.21%; the basic earnings per share were 0.27 yuan"
datetime: "2025-10-22T09:55:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262206753.md)
  - [en](https://longbridge.com/en/news/262206753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262206753.md)
---

# GEMPHARMATECH released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, a year-on-year increase of 11.9%

According to the Zhitong Finance APP, GEMPHARMATECH (688046.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 576 million yuan in the first three quarters, a year-on-year increase of 12.92%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 11.9%; the net profit excluding non-recurring gains and losses was 92.79 million yuan, a year-on-year increase of 29.21%; basic earnings per share were 0.27 yuan

### Related Stocks

- [688046.CN](https://longbridge.com/en/quote/688046.CN.md)

## Related News & Research

- [Nvidia China Optics Send Zhipu Shares Up Nearly 900% Since IPO](https://longbridge.com/en/news/286485723.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)
- [09:15 ETNewport Healthcare's 2025 Outcomes Report Demonstrates Significant Improvements in Teen and Young Adult Mental Health Following Treatment](https://longbridge.com/en/news/286920260.md)